Investigación

Tratamiento del cáncer pediátrico

Buscador de publicaciones

Publicaciones

  • Sánchez-Molina S, Figuerola-Bou E, Blanco ME, Sanchez-Jimenez M, Táboas-Outón P, Gomez-Gonzalez S, Ballaré C, García-Domínguez DJ, Prada-Varela E, Hontecillas-Prieto L, Carcaboso AM, Tirado ÓM, Hernandez-Muñoz MI, de Álava E, Lavarino C, Di Croce L and Mora J.

    RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis

    Science Advances . 6(43): 3058. Nº de citas: 24

    [doi:10.1126/sciadv.aba3058]

  • Bukchin, A, Sanchez-Navarro, M, Carrera, A, Teixido, M, Carcaboso AM, Giralt, E and Sosnik, A.

    Amphiphilic Polymeric Nanoparticles Modified with a Retro-Enantio Peptide Shuttle Target the Brain of Mice

    CHEMISTRY OF MATERIALS . 32(18): 7679-7693. Nº de citas: 15

    [doi:10.1021/acs.chemmater.0c01696]

  • Zugbi S, Ganiewich D, Bhattacharyya A, Aschero MR, Ottaviani D, Sampor C, Cafferata EG, Mena M, Sgroi M, Winter U, Lamas G, Suñol M, Daroqui M, Baialardo E, Salas B, Das A, Fandiño A, Francis JH, Lubieniecki F, Lavarino C, Garippa R, Podhjacer OL, Abramson DH, Radvanyi F, Chantada G, Llera AS and Schaiquevich P.

    Clinical, Genomic, and Pharmacological Study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma

    Cancers . 12(9): . Nº de citas: 24

    [doi:10.3390/cancers12092714]

  • Wiese M, Hamdan FH, Kubiak K, Diederichs C, Gielen GH, Nussbaumer G, Carcaboso AM, Hulleman E, Johnsen SA and Kramm CM.

    Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells

    CELL DEATH & DISEASE . 11(8): 673-673. Nº de citas: 36

    [doi:10.1038/s41419-020-02800-7]

  • Castillo H, Monterrubio C, Pascual-Pastó G, Gomez-Gonzalez S, Garcia-Dominguez DJ, Hontecillas-Prieto L, Resa-Parés C, Burgeño-Sandoval V, Paco-Mercader S, Gene-Olaciregui N, Vilà-Ubach M, Restrepo-Perdomo C, Cuadrado-Vilanova M, Balaguer-Lluna L, Pérez-Jaume S, Castañeda-Heredia A, Santa-María López V, Roldan-Molina M, Suñol M, de Alava E, Mora J, Lavarino C and Carcaboso AM.

    Treatment-driven selection of chemoresistant Ewing sarcoma tumors with limited drug distribution

    JOURNAL OF CONTROLLED RELEASE . 324: 440-449. Nº de citas: 6

    [doi:10.1016/j.jconrel.2020.05.032]

  • Chen KY, Bush K, Klein RH, Cervantes V, Lewis N, Naqvi A, Carcaboso AM, Lechpammer M and Knoepfler PS.

    Reciprocal H3.3 gene editing identifies K27M and G34R mechanisms in pediatric glioma including NOTCH signaling

    Communications Biology . 3(1): 363-363. Nº de citas: 32

    [doi:10.1038/s42003-020-1076-0]

  • Bossacoma F, Cuadrado-Vilanova M, Vinent-Genestar J, Correa MG, Gavrus D, Castillo H, Català-Mora J, Mora J, Schaiquevich P, Chantada G and Carcaboso AM.

    Optimizing the storage of chemotherapeutics for ophthalmic oncology: stability of topotecan solution for intravitreal injection

    OPHTHALMIC GENETICS . 41(4): 397-400. Nº de citas: 1

    [doi:10.1080/13816810.2020.1776336]

  • Fernández-Rodríguez J, Morales-La Madrid A, Gel B, Castañeda-Heredia A, Salvador-Hernandez H, Martínez-Iniesta M, Moutinho C, Morata J, Heyn H, Blanco I, Creus-Bachiller E, Capella G, Farré L, Vidal A, Soldado F, Krauel L, Suñol M, Serra E, Villanueva A and Lázaro C.

    Use of patient derived orthotopic xenograft models for real-time therapy guidance in a pediatric sporadic malignant peripheral nerve sheath tumor

    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY . 12: . Nº de citas: 5

    [doi:10.1177/1758835920929579]

  • Meel MH, de Gooijer MC, Metselaar DS, Sewing ACP, Zwaan K, Waranecki P, Breur M, Buil LCM, Lagerweij T, Wedekind LE, Twisk JWR, Koster J, Hashizume R, Raabe EH, Carcaboso AM, Bugiani M, Phoenix TN, van Tellingen O, van Vuurden DG, Kaspers GJL and Hulleman E.

    Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma

    CLINICAL CANCER RESEARCH . 26(13): 3319-3332. Nº de citas: 42

    [doi:10.1158/1078-0432.CCR-19-3538]

  • Pinto EM, Figueiredo BC, Chen W, Galvao HCR, Formiga MN, Fragoso MCBV, Ashton-Prolla P, Ribeiro EMSF, Felix G, Costa TEB, Savage SA, Yeager M, Palmero EI, Volc S, Salvador-Hernandez H, Fuster-Soler JL, Lavarino C, Chantada G, Vaur D, Odone-Filho V, Brugières L, Else T, Stoffel EM, Maxwell KN, Achatz MI, Kowalski L, de Andrade KC, Pappo A, Letouze E, Latronico AC, Mendonca BB, Almeida MQ, Brondani VB, Bittar CM, Soares EWS, Mathias C, Ramos CRN, Machado M, Zhou W, Jones K, Vogt A, Klincha PP, Santiago KM, Komechen H, Paraizo MM, Parise IZS, Hamilton KV, Wang J, Rampersaud E, Clay MR, Murphy AJ, Lalli E, Nichols KE, Ribeiro RC, Rodriguez-Galindo C, Korbonits M, Zhang J, Thomas MG, Connelly JP, Pruett-Miller S, Diekmann Y, Neale G, Wu G and Zambetti GP.

    XAF1 as a modifier of p53 function and cancer susceptibility.

    Science Advances . 6(26): . Nº de citas: 33

    [doi:10.1126/sciadv.aba3231]